Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

ProMIS Neurosciences Inc.

NASDAQ: PMN · Life Sciences · 5 alerts · CIK 1374339

Share price
$3.31Close, Nov 16
Market cap
$29.8M
Shares outstanding
9MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All ProMIS Neurosciences Inc. filings on SEC EDGAR ↗

4:20 PM ET 10-Q
Financial Results

ProMIS Neurosciences Q3 2026 Results: Net Loss of $8.2M, Loss Narrows

ProMIS Neurosciences reported a significant increase in cash to $44.1 million as of September 30, 2026, compared to $6.1 million at the end of 2025, primarily driven by financing activities that increased additional paid-in capital. The company's accumulated deficit grew to $158.5 million, reflecting ongoing research and development costs, while total shareholders' equity improved to a positive $41.8 million.

Key figure
Net loss $8.2M
4:18 PM ET 8-K
Financial Results

ProMIS Neurosciences Financial Results

ProMIS Neurosciences reported Q3 2026 financial results, ending the period with $44.1 million in cash which is expected to fund operations through 2027. The company reaffirmed that topline data from its Phase 1b PRECISE-AD trial of PMN310 in Alzheimer’s disease remains on track for the first quarter of 2027.

Term
Q3 2026

“The third quarter of 2026 has been productive for ProMIS, following encouraging interim data from our Phase 1b PRECISE-AD trial in Alzheimer’s disease (AD). Based on data generated to date, we continue to believe PMN310 offers a differentiated approach by selectively targeting the most toxic and destructive form of amyloid-beta, the oligomers.”

Neil Warma, President and Chief Executive Officer

“With PRECISE-AD closing out its final stage of patient visits, we look forward to reporting topline data in the first quarter of 2027, which will include safety, biomarker and clinical efficacy measures.”

Neil Warma, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.